Tech Company Financing Transactions
Galux Funding Round
Galux, based in Seoul, secured $29 million from DAYLI Partners, InterVest and Pathway Bioventures.
Transaction Overview
Company Name
Announced On
2/9/2026
Transaction Type
Venture Equity
Amount
$29,000,000
Round
Series B
Investors
Proceeds Purpose
The company intends to use the funds to further enhance its AI platform, expand R&D infrastructure, and accelerate preclinical validation of proprietary pipelines.
Company Information
Company Status
Private & Independent
Industry
Biopharmaceutical
Mailing Address
3-6th floor, 1837, Nambu Sunhwan-ro, Gwanak-gu
Seoul, Undisclosed
Republic of Korea
Seoul, Undisclosed
Republic of Korea
Phone
Website
Email Address
Overview
We aim to redefine how therapeutics are developed: shifting from traditional, screening-based discovery to rational design powered by AI. We envision an ideal platform that enables the zero-shot design of optimal molecules, without relying on trial-and-error or pre-existing templates. We believe that an accurate drug design platform will streamline therapeutic development and deliver safer, more effective medicines to patients.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
Cha-ok Seok
Browse more venture capital transactions:
Prev: 2/9/2026: ThrowMeNot venture capital transaction
Next: 2/9/2026: Modveon venture capital transaction
Share this article
Where The Data Comes From
We do our best to report on every notable VC transaction. All VC database entries reported here are derived from news reports and company announcements. The data comes to us via our partnership with VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs